TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON) (LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, ...
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy ...
Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office Awards Nominated in ...
Faron Pharmaceuticals has collaborated with cancer research organisation City of Hope to develop a Phase II investigator-initiated trial for evaluating bexmarilimab in participants with relapsed or ...
TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel ...
Faron Pharmaceuticals (HEL:FARON) (LSE:FARN) - New translational insights and clinical efficacy will be showcased at EHA 2026, with further context discussed during a post-EHA webcast on 15 June 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results